相关实验视频
Updated: Jun 23, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
在一般外科病房的糖尿病患者中减少胰岛素缺失错误:一项最佳实践实施项目
Sharlyn Jia Yi Ng1, Mien Li Goh2
1Nursing Department, National University Hospital, Singapore.
JBI evidence implementation
|June 24, 2024
概括
实施尽量减少中断的策略减少了成人糖尿病患者的胰岛素遗漏错误. 遵守最佳实践的情况有所改善,在研究期间导致药物错误为零.
科学领域:
- 改善医疗保健质量 改善医疗保健质量
- 患者安全 患者安全
- 基于证据的实践.
背景情况:
- 胰岛素缺失是一种严重的药物错误,具有严重的后果,包括高血糖,昏迷和死亡.
- 高警戒药物错误,特别是胰岛素遗漏,在成人糖尿病患者的护理中构成重大风险.
研究的目的:
- 确定,评估和实施旨在减少需要胰岛素治疗的成年糖尿病患者胰岛素遗漏错误的策略.
- 通过解决一个常见和危险的药物错误来提高患者安全.
主要方法:
- 该项目的指导是JBI证据实施框架,涉及上下文分析,战略实施和结果评估.
- 利用JBI PACES和JBI GRiP工具进行数据收集和规划,重点关注一个基于证据的标准和五个子标准,共22名患者.
主要成果:
- 遵守减少中断和分心的最佳实践从基线 (50%) 增加到后续审计 (45.4%,31.8%).
- 在实施期间,没有发生胰岛素缺失事件,这证明了战略的有效性.
- 虽然护士的合规性有所改善,但由于持续的干扰和遗忘,患者相关的合规性下降,突出了实施障碍.
结论:
- 实施的战略成功地提高了对减少中断和分心的最佳实践的坚持.
- 在实施阶段记录了零胰岛素缺失发生率,显著提高了患者的安全性.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
165
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
165
Hypoglycemia and Glucagon
256
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
256
Diabetes: Management and Pharmacotherapy
257
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
257
Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Insulin Formulations: Types and Delivery
188
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
Short-acting insulins are divided into...
188

